It may not be much of a surprise that narcissistic CEOs of pharmaceutical companies will make bold choices, such as adopting radically new technology. That idea remains true, despite a lengthy correction to a paper that supports it.
The paper, “CEO Narcissism, Audience Engagement, and Organizational Adoption of Technological Discontinuities,” in Administrative Science Quarterly, found support for the following hypothesis:
Continue reading Paper on narcissistic CEOs earns big correction
A former graduate student at Wake Forest School of Medicine “presented falsified and/or fabricated data” in a government-funded drug study, according to findings released by the U.S. Office of Research Integrity earlier today.
The report was released in the wake of an investigation conducted by the university and the ORI. Investigators found that although Brandi Blaylock recorded responses of a dozen laboratory monkeys after giving them anti-abuse drugs, she hadn’t given them the compounds “per protocol.”
Blaylock then presented the data at “two poster presentations, several laboratory meetings, and progress reports.”
Some of her research was supported by a grant from the National Institute of Drug Abuse, “Dopamine D2 Receptors In Primate Models of Cocaine Abuse,” which examined the effects of novel dopamine D3 receptor compounds on drug addiction on monkeys.
However, according to the report, Blaylock presented the falsified responses from a dozen monkeys: Continue reading Former Wake Forest grad student fudged data for drug study
We’ve unearthed a retraction of an editorial titled “Goodbye…”, pulled from Cognition, Technology & Work by its retiring editor after he decided it was “inappropriate.”
The original text is not online. The note in its place reads, in full:
This article has been retracted due to unintended publication.
The author of the editorial is psychologist Erik Hollnagel, based at the University of Southern Denmark, who left the journal after a decade. Interestingly, his own research includes studies of “When Things Go Wrong” (per the title of one of his book chapters), ranging from financial crises to the Fukushima disaster.
The error that led to this reaction seems tiny, in comparison. Hollnagel explains:
Continue reading “Goodbye…”?: Editor pulls farewell editorial after deeming it “inappropriate”
Mario Saad can’t catch a break — yesterday, a Massachusetts judge dismissed his defamation suit against the American Diabetes Association, publisher of Diabetes, which published an expression of concern regarding four of his papers in March.
The researcher has tried — and failed — to use the courts to remove the EoC.
In Saad’s latest attempt to employ legal action against the journal — arguing the EoC was defamatory — the United States District Court of Massachusetts was clear in its ruling (which you can view in its entirety here):
Continue reading Judge dismisses defamation suit against diabetes journal
In case any pilots out there are worrying about their risk of prostate cancer based on a recent meta-analysis that found they are at least twice as likely to develop the disease, they should relax — the paper has been retracted.
The reason: “including inappropriate data from two studies that should be ineligible.”
“The risk of prostate cancer in pilots: a meta-analysis” reviewed eight studies to determine whether airline pilots, who are regularly exposed to radiation and other occupational hazards, have a higher incidence of prostate cancer. However, it also included studies that reported on prostate cancer among all U.S. Armed Forces servicemen, not pilots.
The retraction notice was posted in May — only months after it was published in Aerospace Medicine and Human Performance in February. The notice included a letter to the editor outlining flaws in the meta-analysis and an apologetic response from first author, David Raslau at the Mayo Clinic.
Here’s the notice (appearing at the bottom of page 2):
Continue reading Analysis of pilots with prostate cancer retracted for “inappropriate data”
A group of researchers conducted a clinical trial on hundreds of hypertensive patients. Then, they published the results…six times.
The “nearly identical” papers came to our attention via a retraction in Inflammation. Editor in chief Bruce Cronstein explained how he learned of the mass duplication:
The editors were contacted en masse by somebody doing a Cochrane Review on hypertension and who noticed that the content of the 6 papers was nearly identical. Frankly, not one of us would have noticed otherwise.
Another of those papers, in the European Journal of Pharmaceutical Sciences, has also been retracted. That note is similar to the retraction notice for the Inflammation paper, both of which have been cited twice:
Continue reading “Exactly the same clinical study” published six times
Not so fast — a paper that showed wearing Vibram FiveFingers (resembling foot gloves) “may help reduce running-related injuries” has been removed after the editors realized the first author is on Vibram’s advisory board.
Managing editor Noelle A. Boughanmi told us there’s no retraction here — the journal is just fixing the paper to address the relationship of podiatrist Nick Campitelli with the company featured in the article.
There is still a copy of the paper on PubMed, which suggests these “minimalist shoes” strengthen key muscles.
The paper was published online by the Journal of the American Podiatric Medical Association. It was removed after editors realized that “the author did not fully disclose some involvement with the company,” Boughanmi said:
Continue reading Running shoe paper pulled for failing to disclose author’s industry ties
Justus Liebig University in Germany has been investigating concerns that Joachim Boldt, number two on the Retraction Watch Leaderboard and now up to 92 retractions, may have “manipulated” more data than previously believed.
Until now, the vast majority of Boldt’s retractions were thought to have involved inadequate ethics approval. However, new retraction notices for Boldt’s research suggest that there’s evidence the researcher also engaged in significant data manipulation.
The first retraction from the university investigation emerged last year. Two of three new notices cite the investigation specifically, and an informant at the university told us that there are more retractions to come.
Here are the retracted papers that are freshly on the record, starting with an August retraction for a 1991 Anesthesiology paper (cited 37 times, according to Thomson Scientific’s Web of Knowledge):
Continue reading Three more retractions for former record-holder Boldt, maybe more to come
Editors at BioMed Central have taken the unusual step of updating a retraction notice after an investigation found the authors were not responsible for a peer review process gone awry. The paper is one of dozens of other papers retracted in March for fake peer reviews.
That month, the paper “Clinical application of contrast enhanced ultrasound to diagnose benign prostatic hyperplasia” in Diagnostic Pathology was among the 43 papers retracted due to fake peer reviews. (Retractions for the phenomenon — more about it in our Nature feature here — are up to about 170.)
According to the update posted in July, an investigation into the paper by the Jiading Central Hospital in Shanghai, where the authors work, found that they “did not participate in influencing the peer review process.”
Here’s more from the update to the notice:
A 2003 paper may have left out potentially “significant” data on the long-term side-effects of an antipsychotic drug used in children, according to a former head of the U.S. Food and Drug Administration.
As reported by the Toronto Star, David Kessler is alleging that Janssen, the maker of Risperdal (and owned by Johnson & Johnson), omitted data about the risks of the drug: In particular, that boys who use it over a long period may be at risk of growing breasts.
There’s anecdotal evidence of the side effect. One family claimed the drug had caused their son to grow a pair of 46 DD-sized breasts in a lawsuit against Johnson & Johnson, reported the Wall Street Journal in February. They won, to the tune of $2.5 million. The suit is apparently just one of 1,200 like it.
The abstract of the paper, “Prolactin levels during long-term risperidone treatment in children and adolescents,” published in The Journal of Clinical Psychiatry, suggests that levels of a key hormone aren’t a problem in the long term:
Continue reading Drugmaker accused of omitting side effect data from 2003 Risperdal paper